Key Takeaways
- • Early-stage biotech funding collapsed in Q1 2026: Seed and Series A investments dropped to 50 deals worth $2.3 billion in the first quarter of 2026, down 17% from 60 deals worth $3.7 billion in Q1 2025, placing the sector on track for its worst year of first-time financings since before the pandemic.
- • Later-stage deals gaining traction despite early-stage weakness: Series B and later investments reached $4.5 billion across 51 deals in Q1 2026, exceeding both prior-year periods and widening the funding gap between mature and early-stage companies as investors prioritize lower-risk portfolio defense.
- • Biopharma funding fell 20% in 2025 with IPO activity at decade lows: Annual funding declined significantly last year, with initial public offerings hitting their lowest levels in the past 10 years, reversing post-pandemic recovery momentum and constraining capital access for biotech firms.
- • Late-2025 hedge fund rally lost momentum entering 2026: Most biopharma-focused hedge funds posted single-digit losses in January 2026 despite strong 2025 performance, with top performers like Perceptive Advisors (up 82% in 2025) slipping 2.53% in the opening month as market enthusiasm cooled.
- • M&A and dealmaking show selective acceleration despite funding constraints: Large Series A bets such as $130 million into Slate Medicine and $95 million for Poplar Therapeutics signal investor focus on strategically coherent later-stage transactions with elevated earn-outs, while biotech capital access remains constrained.
Summary
The biopharma sector faces a stark divergence between early-stage and later-stage funding dynamics heading into 2026. According to J.P. Morgan's first-quarter licensing and venture report, seed and Series A investments tracked a significant downturn, with only 50 deals worth $2.3 billion closed in the first three months of 2026—a substantial decline from 60 deals valued at $3.7 billion in the same quarter of 2025. This reversal of momentum places early-stage biotech financings on course for their worst year since before the pandemic, compounding already limited funding opportunities for startups seeking initial capital.
The weakness in early-stage funding contrasts sharply with continued activity in later-stage rounds. J.P. Morgan documented 51 Series B and later investments totaling $4.5 billion in Q1 2026, exceeding deal values from comparable periods in 2024 and 2025. This bifurcation reflects a deliberate investor strategy toward portfolio defense and lower-risk bets, even as specific large rounds continue—including a $130 million Series A for Slate Medicine and a $95 million commitment to Poplar Therapeutics. The widening gap between early- and later-stage capital deployment signals that venture firms are selectively re-entering the market at lower valuations while forcing runway-driven restructurings among unfunded early-stage companies.
Full-year 2025 data underscored the sector's capital constraints. Biopharma funding declined 20% annually, with IPO activity falling to decade lows, reversing the post-pandemic recovery that had characterized 2024-2025. Despite this headwind, dealmaking patterns shifted toward smaller, strategically coherent transactions, with earn-outs and contingent consideration increasingly used to bridge valuation gaps amid regulatory and pricing uncertainty. Public-market performance in 2025 improved equity issuance capacity for larger pharma firms, supporting refinancing flexibility, while biotech companies faced constrained access, with equity deal counts and IPO volumes weakening throughout the year.
Hedge fund performance reflected the sector's volatile trajectory. Most biopharma-focused hedge funds opened 2026 with losses following a strong 2025, with top performer Perceptive Advisors declining 2.53% in January after surging 82% for the full year. Funds such as Janus Henderson Biotech Innovation Fund (down less than 1%) and RA Capital Management (broadly flat) showed relative resilience, but broader declines affected RTW Investments (down 6%), Soleus Capital (down 4.9%), and Averill funds (down 3-4.8%), driven by concentrated long positions and disappointing clinical data disclosures. Despite the January pullback, investor optimism remained intact, supported by stronger balance sheets across companies entering 2026 and steady FDA approval activity in 2025 providing visibility for capital deployment.
The weakness in early-stage funding contrasts sharply with continued activity in later-stage rounds. J.P. Morgan documented 51 Series B and later investments totaling $4.5 billion in Q1 2026, exceeding deal values from comparable periods in 2024 and 2025. This bifurcation reflects a deliberate investor strategy toward portfolio defense and lower-risk bets, even as specific large rounds continue—including a $130 million Series A for Slate Medicine and a $95 million commitment to Poplar Therapeutics. The widening gap between early- and later-stage capital deployment signals that venture firms are selectively re-entering the market at lower valuations while forcing runway-driven restructurings among unfunded early-stage companies.
Full-year 2025 data underscored the sector's capital constraints. Biopharma funding declined 20% annually, with IPO activity falling to decade lows, reversing the post-pandemic recovery that had characterized 2024-2025. Despite this headwind, dealmaking patterns shifted toward smaller, strategically coherent transactions, with earn-outs and contingent consideration increasingly used to bridge valuation gaps amid regulatory and pricing uncertainty. Public-market performance in 2025 improved equity issuance capacity for larger pharma firms, supporting refinancing flexibility, while biotech companies faced constrained access, with equity deal counts and IPO volumes weakening throughout the year.
Hedge fund performance reflected the sector's volatile trajectory. Most biopharma-focused hedge funds opened 2026 with losses following a strong 2025, with top performer Perceptive Advisors declining 2.53% in January after surging 82% for the full year. Funds such as Janus Henderson Biotech Innovation Fund (down less than 1%) and RA Capital Management (broadly flat) showed relative resilience, but broader declines affected RTW Investments (down 6%), Soleus Capital (down 4.9%), and Averill funds (down 3-4.8%), driven by concentrated long positions and disappointing clinical data disclosures. Despite the January pullback, investor optimism remained intact, supported by stronger balance sheets across companies entering 2026 and steady FDA approval activity in 2025 providing visibility for capital deployment.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.